Table A2.
Proportions of Patients Treated With Exemestane Plus Triptorelin With an Estradiol Level Above the Predefined Threshold (2.72 pg/mL) and With Respect to Two Additional Thresholds According to Use of Prior Chemotherapy
| E2 > 2.72 (pg/mL) | E2 > 10 (pg/mL) | E2 > 20 (pg/mL) | E2 ≤ 20 (pg/mL) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Time Point, Months | No. of Patients | Total | No Prior Chemotherapy | Prior Chemotherapy | Total | No Prior Chemotherapy | Prior Chemotherapy | Total | No Prior Chemotherapy | Prior Chemotherapy | Total | No Prior Chemotherapy | Prior Chemotherpy |
| 0 (Baseline) | 83 | 76 (92) | 37 (97) | 39 (87) | 58 (70) | 36 (95) | 22 (49) | 55 (66) | 35 (92) | 20 (44) | 28 (34) | 3 (8) | 25 (56) |
| 3 | 67 | 17 (25) | 10 (37) | 7 (18) | 8 (12) | 7 (26) | 1 (2) | 5 (7) | 4 (15) | 1 (2) | 62 (93) | 23 (85) | 39 (98) |
| 6 | 67 | 16 (24) | 9 (29) | 7 (19) | 8 (12) | 4 (13) | 4 (11) | 4 (6) | 1 (3) | 3 (8) | 63 (94) | 30 (97) | 33 (92) |
| 12 | 65 | 11 (17) | 8 (27) | 3 (9) | 6 (9) | 5 (17) | 1 (3) | 2 (3) | 2 (7) | 0 (0) | 63 (97) | 28 (93) | 35 (100) |
| 3, 6, or 12 | |||||||||||||
| ≥ 1 with E2 > cutoffs | 79 | 27 (34.2) | 16 (45.7) | 11 (25) | 14 (17.7) | 10 (28.6) | 4 (9.1) | 10 (12.7) | 6 (17.1) | 4 (9.1) | 69 (87.3) | 29 (82.9) | 40 (90.9) |
| ≥ 2 with E2 > cutoffs | 13 (16.5) | 6 (7.6) | 1 (1.3) | ||||||||||
NOTE. Data are presented as No. (%). Estradiol (E2) greater than 2.72 pg/mL defines a strict threshold to indicate E2 inconsistent with postmenopausal levels on an aromatase inhibitor. E2 greater than 10 pg/mL defines a less-strict threshold, and thus above which E2 was clearly inconsistent with postmenopausal levels on an aromatase inhibitor. E2 greater than 20 pg/mL defines a threshold above which E2 was inconsistent with gonadotropin-releasing hormone agonist–related postmenopausal status.